Corient Private Wealth LLC Buys Shares of 6,468 Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Corient Private Wealth LLC acquired a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 6,468 shares of the biotechnology company's stock, valued at approximately $786,000.

Several other institutional investors and hedge funds have also recently modified their holdings of SRPT. CBIZ Investment Advisory Services LLC grew its stake in Sarepta Therapeutics by 163.2% during the fourth quarter. CBIZ Investment Advisory Services LLC now owns 587 shares of the biotechnology company's stock valued at $71,000 after acquiring an additional 364 shares in the last quarter. Commonwealth Equity Services LLC grew its position in shares of Sarepta Therapeutics by 22.1% during the fourth quarter. Commonwealth Equity Services LLC now owns 6,357 shares of the biotechnology company's stock valued at $773,000 after purchasing an additional 1,151 shares in the last quarter. Erste Asset Management GmbH increased its holdings in shares of Sarepta Therapeutics by 11.3% in the fourth quarter. Erste Asset Management GmbH now owns 708,248 shares of the biotechnology company's stock worth $86,116,000 after purchasing an additional 72,183 shares during the last quarter. Swiss National Bank increased its holdings in shares of Sarepta Therapeutics by 1.6% in the fourth quarter. Swiss National Bank now owns 168,783 shares of the biotechnology company's stock worth $20,522,000 after purchasing an additional 2,700 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Sarepta Therapeutics by 88.2% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 147,236 shares of the biotechnology company's stock worth $17,902,000 after buying an additional 68,992 shares in the last quarter. Institutional investors own 86.68% of the company's stock.

Remove Ads

Sarepta Therapeutics Trading Down 1.9 %

Shares of NASDAQ SRPT traded down $1.40 during mid-day trading on Friday, reaching $70.41. The company had a trading volume of 984,471 shares, compared to its average volume of 1,256,653. Sarepta Therapeutics, Inc. has a 52 week low of $69.81 and a 52 week high of $173.25. The business's 50-day moving average is $102.66 and its 200-day moving average is $115.99. The stock has a market cap of $6.83 billion, a price-to-earnings ratio of 56.33 and a beta of 0.79. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93.

Wall Street Analyst Weigh In

A number of research firms have issued reports on SRPT. HC Wainwright reaffirmed a "sell" rating and issued a $75.00 price objective on shares of Sarepta Therapeutics in a research note on Wednesday, March 19th. Royal Bank of Canada reduced their price target on shares of Sarepta Therapeutics from $165.00 to $161.00 and set an "outperform" rating on the stock in a research report on Thursday, February 27th. Scotiabank lowered their price objective on shares of Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating for the company in a research report on Thursday, March 20th. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating for the company in a research note on Wednesday, March 19th. Finally, Needham & Company LLC restated a "buy" rating and set a $202.00 target price on shares of Sarepta Therapeutics in a research report on Tuesday, March 18th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Sarepta Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $167.41.

Insider Buying and Selling

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the company's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the sale, the director now directly owns 27,812 shares in the company, valued at approximately $2,771,187.68. This represents a 8.22 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 7.70% of the stock is owned by insiders.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.